Current Report Filing (8-k)
August 05 2020 - 5:21PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
August 5, 2020
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
11682 El Camino Real, Suite 300
San Diego, CA
|
|
92130
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
|
|
|
|
Registrant’s telephone number, including
area code: (858) 997-2400
(Former name or Former Address, if Changed Since
Last Report.)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b)
of the Exchange Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on
which registered
|
Common Stock
|
|
ADMP
|
|
NASDAQ Capital Market
|
On August 5, 2020, Adamis Pharmaceuticals
Corporation (the “Company”) received a letter from the Listing Qualifications Department of The NASDAQ Stock Market
LLC (“Nasdaq”) notifying the Company that as a result of the closing bid price of the Company’s common stock
having been at $1.00 per share or greater for at least ten consecutive business days, the Company has regained compliance
with Nasdaq’s minimum bid price requirement under Nasdaq's Marketplace Rule 5550(a)(2) for continued listing on The NASDAQ
Capital Market, and the matter is now closed. On October 11, 2019, the Company was notified by Nasdaq that it was not in compliance
with the minimum bid price rule because the common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive
business days as required by Nasdaq’s listing rules. The Company received additional communications from Nasdaq in April
2020 that ultimately extended the deadline to regain compliance to December 21, 2020. From July 22, 2020 to August 4, 2020, the
Company’s closing bid price for ADMP has been at $1.00 per share or greater.
A copy of a press release issued by the Company
on August 5, 2020 regarding the above matters is filed as Exhibit 99.1 to this Current Report
on Form 8-K.
|
Item 9.01
|
Financial Statements and Exhibits
|
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press
release issued by the Company dated August 5, 2020.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
Dated: August
5, 2020
|
By:
|
/s/ Robert O. Hopkins
|
|
Name:
|
Robert O. Hopkins
|
|
Title:
|
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Sep 2023 to Sep 2024